Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either relapsed/refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Patients with relapsed Burkitt lymphoma or those who have double- or triple-hit lymphoma have no viable treatment options, says Noy. Currently, the National Comprehensive Cancer Network guidelines state that these patients should receive any therapy they have not already been exposed to. In a prior study, devimistat showed durable activity in a patient with primary refractory Burkitt lymphoma, which enabled them to undergo resection, says Noy.

A phase II trial (NCT03793140) was launched to evaluate the activity of devimistat in a larger cohort of patients. In the ongoing trial, patients are being grouped into 2 cohorts. Cohort 1 is enrolling patients with primary refractory or relapsed Burkitt lymphoma, and cohort 2 is enrolling patients with double-hit and triplet-hit lymphoma, concludes Noy.